TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02962843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IY TCM
Description: The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 \& 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills \& Problem Solving.
Study: NCT03720392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT
Description: FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
Study: NCT03441217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine Butylbromide 20Mg/1mL Injection
Description: Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
Study: NCT01910077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrobell capsule 1mg
Description: 1 capsule, oral, over the period I\&II(crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf capsule 1mg
Description: 1 capsule, oral, over the period I\&II(crossover)
Study: NCT01278927

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Stress Management
Description: Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
Study: NCT02282787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXMEDETOMIDINE
Description: Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
Study: NCT04537780

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tabled every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 10 mg daily at bed time.
Study: NCT03489954

Intervention type: OTHER
Intervention: Evaluation
Description: Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.

Intervention type: OTHER
Intervention: Evaluation
Description: Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
Study: NCT00821509

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand washing
Description: Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
Study: NCT03244657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept ophthalmic injection （0.5mg）
Description: The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept ophthalmic injection （0.5mg）
Description: In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given.
Study: NCT00480857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Description: Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
Study: NCT00617305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
Study: NCT00998439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please
Description: * 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent® II
Description: * 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug
Study: NCT00617305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
Study: NCT02329197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (HCG)
Description: intrauterine injection of HCG prior to embryo transfer in an IVF cycle
Study: NCT04934618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carelizumab Combined With Irinotecan and Apatinib
Description: Three-drug regimen was used in second-line treatment of Advanced gastric cancer
Study: NCT02258620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinitrate isosorbide
Description: dinitrate isosorbide (cedocard\*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard\*) 5 mg by intra arterial direct in the sheat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinitrate isosorbide
Description: dinitrate isosorbide (cedocard\*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard\*) 5 mg by intra arterial direct in the sheat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerine
Description: nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
Study: NCT01265056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill is administered similar to the protocol used for the investigational drug.
Study: NCT01387633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
Description: For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention group for people with diabetes through Diabetes Conversation Maps
Description: For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
Study: NCT00801970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Treatment
Description: 15 weekly therapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Treatment
Description: 15 weekly therapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Therapy
Description: 3 months of weekly group therapy sessions.
Study: NCT03225456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: Intra-nasal oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intra-nasal placebo
Study: NCT02711852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Administered as oral capsules
Study: NCT00821509

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disinfectant rubbing
Description: Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
Study: NCT00473980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin, celecoxib, esomeprazole

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Indomethacin, celecoxib, esomeprazole
Study: NCT00807573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Day 1: Paclitaxel (90 mg/m\^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m\^2 over 60 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Day 1: Pemetrexed (500 mg/m\^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
Study: NCT04058171

Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill walking test
Description: Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.

Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill walking test
Description: Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
Study: NCT02412852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrite
Description: Sustained release formulation of sodium nitrite
Study: NCT04058171

Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill walking test
Description: Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
Study: NCT01763164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
Study: NCT03883269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin 4% topical gel formulation
Description: Erythromycin 4% topical gel formulation, BID, 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1% topical lotion formulation
Description: Clindamycin 1% topical lotion formulation, BID, 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 70% topical ethanol solution
Description: 70% topical ethanol solution, BID, 4 weeks
Study: NCT01484964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study: NCT00989989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham ranibizumab
Description: Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham laser photocoagulation
Description: Sham laser treatment administered at day 1.
Study: NCT03683602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF group
Description: PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy group
Description: Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain.
Study: NCT03384329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol Pill
Description: Resveratrol 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Pills
Study: NCT03609255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behavior
Description: Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing stress
Description: Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: An educational handout for sedentary behavior and weekly neutral topic videos
Study: NCT00712348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Intravenous infusion every 2 weeks
Study: NCT03436784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indiana SNAP-Ed
Description: First four Indiana SNAP-Ed nutrition education lessons served as the intervention
Study: NCT03124069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Saturn
Description: Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
Study: NCT03070743

Intervention type: PROCEDURE
Intervention: Posterior Approach Compression Distraction Reduction Surgery
Description: Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
Study: NCT00217464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: intramuscularly
Study: NCT00986284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
Study: NCT02900144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Comprehensive Behavioral Intervention for Tics
Description: In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Behavioral Intervention for Tics
Description: In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
Study: NCT00720018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Sumatriptan Iontophoretic Transdermal Patch
Description: NP101 transdermal patch delivering sumatriptan for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Sumatriptan Iontophoretic Transdermal Patch
Description: NP101 transdermal patch delivering sumatriptan for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Sumatriptan Iontophoretic Transdermal Patch
Description: NP101 transdermal patch delivering sumatriptan for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Sumatriptan Iontophoretic Transdermal Patch
Description: NP101 transdermal patch delivering sumatriptan for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 Sumatriptan Iontophoretic Transdermal Patch
Description: NP101 transdermal patch delivering sumatriptan for 4 hours.
Study: NCT00718562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMN107